73 related articles for article (PubMed ID: 19783964)
1. The use of nanoferromagnetics to increase the cytotoxic effect of antitumor drugs.
Chekhun VF; Todor IN; Lukyanova NY; Shpyleva SI; Naleskina LA; Khaetsky IK; Kulik GI
Exp Oncol; 2009 Sep; 31(3):163-7. PubMed ID: 19783964
[TBL] [Abstract][Full Text] [Related]
2. Involvement of doxorubicin-induced Fas expression in the antitumor effect of doxorubicin on Lewis lung carcinoma in vivo.
Yoshimoto Y; Kawada M; Ikeda D; Ishizuka M
Int Immunopharmacol; 2005 Feb; 5(2):281-8. PubMed ID: 15652759
[TBL] [Abstract][Full Text] [Related]
3. Preparation and characterization of HA-PEG-PCL intelligent core-corona nanoparticles for delivery of doxorubicin.
Yadav AK; Mishra P; Jain S; Mishra P; Mishra AK; Agrawal GP
J Drug Target; 2008 Jul; 16(6):464-78. PubMed ID: 18604659
[TBL] [Abstract][Full Text] [Related]
4. In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P450 3A.
Quintieri L; Rosato A; Napoli E; Sola F; Geroni C; Floreani M; Zanovello P
Cancer Res; 2000 Jun; 60(12):3232-8. PubMed ID: 10866316
[TBL] [Abstract][Full Text] [Related]
5. Proanthocyanidin from grape seeds enhances doxorubicin-induced antitumor effect and reverses drug resistance in doxorubicin-resistant K562/DOX cells.
Zhang XY; Li WG; Wu YJ; Bai DC; Liu NF
Can J Physiol Pharmacol; 2005 Mar; 83(3):309-18. PubMed ID: 15870845
[TBL] [Abstract][Full Text] [Related]
6. Schedule-dependent interaction between Doxorubicin and mTHPC-mediated photodynamic therapy in murine hepatoma in vitro and in vivo.
Kirveliene V; Grazeliene G; Dabkeviciene D; Micke I; Kirvelis D; Juodka B; Didziapetriene J
Cancer Chemother Pharmacol; 2006 Jan; 57(1):65-72. PubMed ID: 16001168
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxicity of Fe3O4/Au composite nanoparticles loaded with doxorubicin combined with magnetic field.
Chao X; Shi F; Zhao YY; Li K; Peng ML; Chen C; Cui YL
Pharmazie; 2010 Jul; 65(7):500-4. PubMed ID: 20662318
[TBL] [Abstract][Full Text] [Related]
8. Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin.
Yadav AK; Mishra P; Mishra AK; Mishra P; Jain S; Agrawal GP
Nanomedicine; 2007 Dec; 3(4):246-57. PubMed ID: 18068091
[TBL] [Abstract][Full Text] [Related]
9. In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model.
Wong HL; Rauth AM; Bendayan R; Wu XY
Eur J Pharm Biopharm; 2007 Mar; 65(3):300-8. PubMed ID: 17156986
[TBL] [Abstract][Full Text] [Related]
10. Relationships between the in vitro cytotoxicity and transport characteristics of pirarubicin and doxorubicin in M5076 ovarian sarcoma cells, and comparison with those in Ehrlich ascites carcinoma cells.
Nagai K; Nagasawa K; Sadzuka Y; Tsujimoto M; Takara K; Ohnishi N; Yokoyama T; Fujimoto S
Cancer Chemother Pharmacol; 2002 Mar; 49(3):244-50. PubMed ID: 11935217
[TBL] [Abstract][Full Text] [Related]
11. Effect of methimazole treatment on doxorubicin-induced cardiotoxicity in mice.
Osman AM; Nemnem MM; Abou-Bakr AA; Nassier OA; Khayyal MT
Food Chem Toxicol; 2009 Oct; 47(10):2425-30. PubMed ID: 19577608
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo antitumor effects of doxorubicin loaded with bacterial magnetosomes (DBMs) on H22 cells: the magnetic bio-nanoparticles as drug carriers.
Sun JB; Duan JH; Dai SL; Ren J; Zhang YD; Tian JS; Li Y
Cancer Lett; 2007 Dec; 258(1):109-17. PubMed ID: 17920762
[TBL] [Abstract][Full Text] [Related]
13. [Preparation of doxorubicin encapsulated in amphiphilic polysaccharide nanoparticles and anti-hepatocarcinoma effect thereof].
Huang YF; Gu WL; Li ZH; Chen RF; Zhou JJ; Zhou QB; Guo N
Zhonghua Yi Xue Za Zhi; 2009 Mar; 89(12):810-2. PubMed ID: 19595118
[TBL] [Abstract][Full Text] [Related]
14. Combined effects of buthionine sulfoximine and cepharanthine on cytotoxic activity of doxorubicin to multidrug-resistant cells.
Kisara S; Furusawa S; Murata R; Ogata M; Hikichi N; Takayanagi Y; Sasaki K
Oncol Res; 1995; 7(3-4):191-200. PubMed ID: 8555653
[TBL] [Abstract][Full Text] [Related]
15. Synergistic effect of probimane on anticancer cytotoxicity of doxorubicin in vitro.
Zhang Y; Ye QX; Liu J; Zhang ZY; Zhang TM
Zhongguo Yao Li Xue Bao; 1994 Jan; 15(1):56-9. PubMed ID: 8010087
[TBL] [Abstract][Full Text] [Related]
16. [Synergism of sobuzoxane in combination with doxorubicin against leukemia P388 in mice].
Dai ZQ; Xu JY; Yuan XJ; Cai JC
Zhongguo Yao Li Xue Bao; 1996 Jan; 17(1):69-71. PubMed ID: 8737460
[TBL] [Abstract][Full Text] [Related]
17. Screening of biochemical modulator by tumor cell permeability of doxorubicin.
Sadzuka Y; Hatakeyama H; Daimon T; Sonobe T
Int J Pharm; 2008 Apr; 354(1-2):63-9. PubMed ID: 18054183
[TBL] [Abstract][Full Text] [Related]
18. The antitumor effects of tetrodotoxin and/or doxorubicin on Ehrlich ascites carcinoma-bearing female mice.
El-Dayem SM; Fouda FM; Ali EH; Motelp BA
Toxicol Ind Health; 2013 Jun; 29(5):404-17. PubMed ID: 22317827
[TBL] [Abstract][Full Text] [Related]
19. Cardiotoxicity of doxorubicin/paclitaxel combination in rats: effect of sequence and timing of administration.
Saad SY; Najjar TA; Alashari M
J Biochem Mol Toxicol; 2004; 18(2):78-86. PubMed ID: 15122649
[TBL] [Abstract][Full Text] [Related]
20. [Antitumor effect and mechanism of shikonin derivative SYUNZ-7].
Huang H; Xie BF; Zhu XF; Feng GK; Zhou JM; Wang Y; Wu HQ; Huang ZS; Gu LQ; Liu ZC
Ai Zheng; 2005 Dec; 24(12):1453-8. PubMed ID: 16351791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
